Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,... see more

GREY:ATBPF - Post Discussion

Antibe Therapeutics Inc(Pre-Merger) > Canaccord Genuity managers seek to take firm private
View:
Post by Forestview on Jan 09, 2023 11:23am

Canaccord Genuity managers seek to take firm private

Article below.  Anyone see an impact on Antibe as a result?  


https://financialpost.com/fp-finance/canaccord-genuity-managers-take-firm-private-1-13-billion

Canaccord Genuity Group Inc.’s management group is seeking to take the firm private in a $1.13-billion deal, taking advantage of a plunge in the share price after last year’s turmoil in capital markets.

The management group — which includes the firm’s chief executive, chair and more than a dozen other senior executives — owns a combined 21 per cent of the shares, the group said in a statement on Monday. Canaccord’s largest outside shareholder also supports the bid of $11.25 per share, according to the statement.

Canaccord’s stock has fallen by 48 per cent since a pandemic-era peak in November 2021, as volatile markets and plunging global equity prices put a chill in the initial public offerings and other transactions the firm specializes in. The deal would return the company — which was founded as a regional brokerage in 1950 — to private markets after 18 years.

“The common shares, which naturally reflect the inherent volatility of the global capital markets in which the company operates, have proven to be not well-suited for trading in a public marketplace,” chief executive Dan Daviau said in the statement. “As an employee-owned business, the company will be able to focus its efforts solely on advancing its proven strategies in ways that serve the best interests of its clients.”

Comment by MrMugsy on Jan 09, 2023 1:58pm
Not at all Forestview. I am very glad that ATE is public and I don't think they're looking to change that. Money-managing is also very different than what we're doing.  They don't have the same luxury of huge spikes on P2 data results and then spikes on P3 partnering. The only similarity is ... that the buyers had al vanished for a wee bit before P2.  That was our ...more  
Comment by MrMugsy on Jan 09, 2023 1:59pm
Our buying cue ! hahaha : )
Comment by Forestview on Jan 09, 2023 2:26pm
Hey Mugs, I meant from the perspective that Canaccord is an investor in ATE.  Any potential impact from that? 
Comment by MrMugsy on Jan 09, 2023 2:50pm
These investors are tiny - we're really looking for the big boys to get in. Hoping that's the case in 2023. We have 2 US investment groups and 4 Canadian. All small in my opinion. We can do without.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities